Jan 10, 2024 / 12:30AM GMT
Brian Cheng - J.P. Morgan Securities LLC - Analyst
Good afternoon. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. I'm joined by my associate, Sean Kim, who is also in the audience.
On stage, we have the team from Editas. I'll pass the mic to their CEO, Gilmore O'Neill, for a short presentation, followed by a live audience Q&A. (Conference Instructions) Gilmore, the stage is yours.
Gilmore O'Neill - Editas Medicine Inc - President & CEO
Thank you very much, Brian. Good afternoon, everyone. It's great and we're very grateful to have you here as we tell you about Editas, what we have done in the past year, share an update on the data that we presented at ASH just recently for our lead clinical asset, and talk about our plans for the future into 2024.
Now, before going any further, you should know that I'm going to make forward-looking statements and the actual results may be materially different. And so we
Editas Medicine Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers